CJC-1295 + Ipamorelin · 5mg/5mg blend · research use only
CJC-1295 + ipamorelin dosage, read as a two-peptide blend.
CJC-1295 and ipamorelin are dosed together for a reason that also shapes how they are dosed: one is a GHRH analog and the other a GHRP, acting on two different receptors. That mechanism pairing is why research protocols model them as a single blend with matched microgram amounts, and the short no-DAC half-life is why those amounts are split across the day rather than given once. This page lays out the ranges, timing, and reconstitution math reported in the literature for a 5mg/5mg blend — framed as a research reference, not a human protocol or medical advice.
Two receptors, one blend
CJC-1295 is a growth-hormone-releasing hormone (GHRH) analog; ipamorelin is a selective growth-hormone-releasing peptide (GHRP) acting on the ghrelin receptor. Because they recruit growth-hormone release through two distinct pathways, research protocols model them together — commonly at matched microgram amounts — rather than separately. The blend is the unit of dosing, which is why Titan supplies them as a single 5mg/5mg vial.
CJC-1295 vs ipamorelin →Microgram ranges in the literature
Research references commonly model the pair in micrograms — frequently around 100 mcg of each per administration — given one to three times daily in study designs. Because the two are blended at a 1:1 milligram ratio in Titan's vial, a single measured draw delivers both components in the same proportion. The figures are a laboratory reference, not a human protocol.
Full research guide →No-DAC half-life drives timing
CJC-1295 exists in two forms: with DAC (drug affinity complex), which extends the half-life to days, and without DAC (mod GRF 1-29), whose half-life is on the order of minutes. The blend most studied alongside ipamorelin uses the short no-DAC form, and ipamorelin itself clears within a couple of hours — which is why research designs split administrations across the day and often time them to fasted or pre-sleep windows.
DAC vs no-DAC explained →Reconstitution math, 5mg/5mg vial
Titan's blend ships as a combined 5mg CJC-1295 + 5mg ipamorelin lyophilized vial. Reconstitute with bacteriostatic water: add 2 mL and the vial is 2.5 mg/mL of each component, so 0.1 mL delivers 250 mcg of each and 0.04 mL delivers 100 mcg of each. Because both peptides are in one vial, a single draw scales them together — confirm against the calculator before any in-vitro work.
Run the numbers →A blend COA must confirm both
A single-peptide certificate of analysis cannot validate a blend. A real COA for this vial confirms the identity and purity of CJC-1295 and ipamorelin separately, plus the ratio between them — a one-line purity number for a two-peptide product is a red flag. Titan's blend ships with mass-spec identity and HPLC purity against a ≥99% internal target, lot-matched.
Blend COA red flags →Research-use framing
Neither CJC-1295 nor ipamorelin has regulatory approval for human use. The ranges and timing here are reproduced as a laboratory research reference for in-vitro and modelling work — not instructions for human use. Titan supplies the blend strictly as a research reagent, and nothing on this page is medical or dosing advice.
Research-use policy →The detail, in plain terms
The blend dosing reference, in one table.
The variables a research protocol weighs for the CJC-1295 / ipamorelin pair — mechanism, microgram amounts, the half-life that drives timing, and the reconstitution math for a 5mg/5mg vial. Reproduced as a reference, not a human protocol.
- Components
- CJC-1295 (GHRH analog, no-DAC form) + ipamorelin (selective GHRP).
- Blend ratio
- 1:1 by mass — 5mg CJC-1295 + 5mg ipamorelin per vial.
- Reference amount
- ≈100 mcg of each per administration in study designs.
- Frequency
- 1–3 administrations daily in research protocols (short half-life).
- Half-life
- No-DAC CJC-1295 ≈ minutes; ipamorelin ≈ a couple of hours.
- Reconstitution
- 2 mL BAC water → 2.5 mg/mL each (0.04 mL = 100 mcg of each).
Questions researchers ask
Before you order.
- What is the research dosage for a CJC-1295 / ipamorelin blend?
- Research references commonly model the pair at matched microgram amounts — frequently around 100 mcg of each per administration, given one to three times daily in study designs. Because Titan's vial blends the two at a 1:1 milligram ratio, a single measured draw delivers both in the same proportion. These figures are a laboratory reference, not a human dosing protocol or medical advice.
- Why are CJC-1295 and ipamorelin dosed together?
- They act on two different pathways — CJC-1295 is a GHRH analog and ipamorelin is a selective GHRP (ghrelin-receptor agonist). Research protocols pair them because the two mechanisms are studied for a combined effect on growth-hormone release that neither produces alone. That is why they are supplied and modelled as a single blend rather than separately.
- Why is the blend dosed multiple times a day?
- The CJC-1295 form studied alongside ipamorelin is usually the no-DAC version (mod GRF 1-29), whose half-life is on the order of minutes, and ipamorelin clears within a couple of hours. Because both are short-acting, research designs split administrations across the day and often time them to fasted or pre-sleep windows. A DAC form of CJC-1295 has a much longer half-life and is modelled differently.
- How do I reconstitute a 5mg/5mg CJC-1295 / ipamorelin vial?
- Add bacteriostatic water to the combined lyophilized vial. Adding 2 mL makes it 2.5 mg/mL of each component, so 0.1 mL delivers 250 mcg of each and 0.04 mL delivers 100 mcg of each. Because both peptides share one vial, a single draw scales them together. Always confirm against the reconstitution calculator before any in-vitro work.
- Is CJC-1295 / ipamorelin approved for human use?
- No. Neither component has regulatory approval for human use. Titan Peptide Lab supplies the blend strictly as a research-use-only reagent for in-vitro laboratory work — not for human or animal consumption, and not for diagnostic, therapeutic, or preventative use.